                                          ABSTRACT
The invention relates to compositions and methods for the preparation, manufacture and
therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts
and oncology-related mmRNA molecules. The present invention provides an isolated
polynucleotide comprising a first region of linked nucleosides, said first region encoding the
oncology-related polypeptide of interest, a first flanking region located at the 5' terminus of
said first region comprising a sequence of linked nucleosides selected from the group
consisting of the native 5' untranslated region (UTR) of any of SEQ ID NOs: 4704-9203,
SEQ ID NOs: 1-4 and functional variants thereof and a second flanking region located at the
3' terminus of said first region comprising a sequence of linked nucleosides selected from
the group consisting of the native 3' UTR of any of SEQ ID NOs: 4704-9203, SEQ ID NOs:
5-21 and functional variants thereof and a 3' tailing sequence of linked nucleosides.

DUE TO SIZE CONSIDERATIONS THE DESCRIPTION FOR THIS DIVISIONAL
   APPLICATION  IS BEING FILED SEPARATELY BY PHYSICAL MEDIA
                     DIRECT TO IP AUSTRALIA

WO 2013/151672                                                          PCT/US2013/030070
                                          Claims
We claim:
   1. A method of treating a disease, disorder and/or condition in a subject in need
       thereof by increasing the level of an oncology-related polypeptide of interest
       comprising administering to said subject an isolated polynucleotide encoding said
       oncology-related polypeptide.
   2. A method of reducing and/or ameliorating at least one symptom of cancer in a
       subject need thereof by increasing the level of an oncology-related polypeptide of
       interest comprising administering to said subject an isolated polynucleotide
       encoding said oncology-related polypeptide.
   3.  The method of claim 2 wherein the at least one symptom of cancer is tumor
       growth.
   4. The method of claim 1 wherein the disease, disorder and/or condition is selected
       from the group consisting of adrenal cortical cancer, advanced cancer, anal
       cancer, aplastic anemia, bileduct cancer, bladder cancer, bone cancer, bone
       metastasis, brain tumors, brain cancer, breast cancer, childhood cancer, cancer of
       unknown primary origin, Castleman disease, cervical cancer, colon/rectal cancer,
       endometrial cancer, esophagus cancer, Ewing family of tumors, eye cancer,
       gallbladder cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal
       tumors, gestational trophoblastic disease, Hodgkin disease, Kaposi sarcoma, renal
       cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphocytic
       leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic
       myeloid leukemia, chronic myelomonocytic leukemia, liver cancer, non-small cell
       lung cancer, small cell lung cancer, lung carcinoid tumor, lymphoma of the skin,
       malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, nasal
       cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non
       Hodgkin lymphoma, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian
                                            943

WO 2013/151672                                                        PCT/US2013/030070
     cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer,
     retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma in adult soft
     tissue, basal and squamous cell skin cancer, melanoma, small intestine cancer,
     stomach cancer, testicular cancer, throat cancer, thymus cancer, thyroid cancer,
     uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia,
     Wilms tumor and secondary cancers caused by cancer treatment.
 5. The method of claim 3 wherein the tumor growth is results from a disease,
     disorder and/or condition selected from the group consisting of adrenal cortical
     cancer, advanced cancer, anal cancer, aplastic anemia, bileduct cancer, bladder
     cancer, bone cancer, bone metastasis, brain tumors, brain cancer, breast cancer,
     childhood cancer, cancer of unknown primary origin, Castleman disease, cervical
     cancer, colon/rectal cancer, endometrial cancer, esophagus cancer, Ewing family
     of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumors,
     gastrointestinal stromal tumors, gestational trophoblastic disease, Hodgkin
     disease, Kaposi sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal
     cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic
     lymphocytic leukemia, chronic myeloid leukemia, chronic myelomonocytic
     leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, lung
     carcinoid tumor, lymphoma of the skin, malignant mesothelioma, multiple
     myeloma, myelodysplastic syndrome, nasal cavity and paranasal sinus cancer,
     nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, oral cavity and
     oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile
     cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma,
     salivary gland cancer, sarcoma in adult soft tissue, basal and squamous cell skin
     cancer, melanoma, small intestine cancer, stomach cancer, testicular cancer, throat
     cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar
     cancer, Waldenstrom macroglobulinemia, Wilms tumor and secondary cancers
     caused by cancer treatment.
                                          944

WO 2013/151672                                                         PCT/US2013/030070
 6. The method of any of claims 1 or 2 wherein the administration of the isolated
      polynucleotide reduces the number of cancer cells, eliminates cancer cells,
      prevents an increase in cancer cells and/or alleviates the symptoms of cancer in a
      subject.
 7. The method of claim 2 wherein the at least one symptom of cancer is selected
      from the group consisting of weakness, aches and pains, fever, fatigue, weight
      loss, blood clots, increased blood calcium levels, low white blood cell count, short
      of breath, dizziness, headaches, hyperpigmentation, jaundice, erthema, pruritis,
      excessive hair growth, change in bowel habits, change in bladder function, long
      lasting sores, white patches inside the mouth, white spots on the tongue, unusual
      bleeding or discharge, thickening or lump on parts of the body, indigestion,
      trouble swallowing, changes in warts or moles, change in new skin and nagging
      cough or hoarseness.
 8.   The methods of any of claims 1 or 2, wherein the isolated polynucleotide is
      formulated.
 9. The method of claim 8, wherein the formulation comprises a lipid which is
      selected from one of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA, 98N12-5,
      C12-200, DLin-MC3-DMA, PLGA, PEG, PEG-DMG, PEGylated lipids and
      mixtures thereof.
  10. The method of claim 9, wherein the isolated polynucleotide is administered at a
      total daily dose of between 0.001 ug and 150 ug.
  11. The method of claim 10, wherein administration is by injection, topical
      administration, ophthalmic administration and intranasal administration.
                                           945

WO 2013/151672                                                            PCT/US2013/030070
  12. The method of claim 11, wherein administration is by injection and said injection
      is selected from the group consisting of intradermal, subcutaneous and
      intramuscular.
  13. The method of claim 12, wherein administration is topical administration and said
      topical administration is selected from the group consisting of cream, lotion,
      ointment, gel, spray, solution and the like.
  14. The method of claim 13, wherein the topical administration further comprises a
      penetration enhancer.
  15. The method of claim 14 where the penetration enhancer is selected from the
      group consisting of surfactants, fatty acids, bile salts, chelating agents, non
      chelating non-surfactants, polyoxyethylene-9-lauryl ether, polyoxyethylene-20
      cetyl ether, fatty acids and/or salts in combination with bile acids and/or salts,
      sodium salt in combination with lauric acid, capric acid and UDCA, and the like.
  16. An isolated polynucleotide comprising:
      (a) a first region of linked nucleosides, said first region encoding an oncology
          related polypeptide of interest selected from the group consisting of SEQ ID
          NOs: 4704-9203;
      (b) a first flanking region located at the 5' terminus of said first region
          comprising;
               (i)     a sequence of linked nucleosides selected from the group
                       consisting of the native 5' untranslated region (UTR) of any of the
                       nucleic acids that encode any of SEQ ID NOs: 4704-9203, SEQ ID
                       NO: 1-4 and functional variants thereof;
      (c) a second flanking region located at the 3' terminus of said first region
          comprising;
               (i')    a sequence of linked nucleosides selected from the group
                       consisting of the native 3' UTR of any of the nucleic acids that
                                             946

WO 2013/151672                                                        PCT/US2013/030070
                     encode any of SEQ ID NOs: 4704-9203, SEQ ID NOs 5-21 and
                     functional variants thereof; and
              (ii')  a 3' tailing sequence of linked nucleosides.
  17. The isolated polynucleotide of claim 16 wherein the first region of linked
      nucleosides comprises at least an open reading frame of a nucleic acid sequence,
      wherein the nucleic acid sequence is selected from the group consisting of SEQ
      ID NOs: 4667-4703 and 9204-33882.
  18. The isolated polynucleotide of claim 16, wherein the first region further
      comprises two stop codons.
  19. The isolated polynucleotide of claim 16, wherein the first region further
      comprises a first stop codon "TGA" and a second stop codon selected from the
      group consisting of "TAA," "TGA" and "TAG."
 20. The isolated polynucleotide of claim 16, wherein the 3' tailing sequence of linked
      nucleosides is selected from the group consisting of a poly-A tail of
      approximately 160 nucleotides and a poly A-G quartet.
 21. The isolated polynucleotide of claim 16, wherein the first flanking region further
      comprises at least one 5'terminal cap.
 22. The isolated polynucleotide of claim 21, wherein the at least one 5' terminal cap is
      selected from the group consisting of CapO, Cap 1, ARCA, inosine, NI-methyl
      guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino
      guanosine, LNA-guanosine, and 2-azido-guanosine.
 23. The isolated polynucleotide of any of claims 16-22 where the isolated
      polynucleotide is substantially purified.
                                           947

WO 2013/151672                                                       PCT/US2013/030070
 24. The isolated polynucleotide of any one of claims 16-22, wherein said nucleotides
     comprise at least two modifications and a translatable region.
 25. The isolated polynucleotide of claim 24, wherein the modifications are located on
     one or more of a nucleoside and/or the backbone of said nucleotides.
 26. The isolated polynucleotide of claim 25, where the modifications are located on
     both a nucleoside and a backbone linkage.
 27. The isolated polynucleotide of claim 25, where the modifications are located on
     the backbone linkage.
 28. The isolated polynucleotide of claim 27, where the backbone linkage is modified
     by replacement of one or more oxygen atoms.
 29. The isolated polynucleotide of claim 27, where the modifications comprises
     replacing at least one phosphodiester linkage with a phosphorothioate linkage.
 30. The isolated polynucleotide of claim 25, where the modifications are located on a
     nucleoside.
 31. The isolated polynucleotide of claim 27, where the modifications are on a sugar of
     the nucleoside.
 32. The isolated polynucleotide of claim 30, where the modifications are selected
     from the group consisting of pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio
     5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5
     hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl
     pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5
     taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio
     uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl
                                          948

WO 2013/151672                                                       PCT/US2013/030070
     pseudouridine, 4-thio- 1-methyl-pseudouridine, 2-thio- 1-methyl-pseudouridine, 1
     methyl-i -deaza-pseudouridine, 2-thio- 1-methyl-i -deaza-pseudouridine,
     dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio
     dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy
     pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine,
     pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4
     methylcytidine, 5-hydroxymethylcytidine, i-methyl-pseudoisocytidine, pyrrolo
     cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4
     thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1
     deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza
     zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2
     methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine,
     4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2, 6-diaminopurine, 7
     deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2
     aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, I
     methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis
     hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)
     adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2
     methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7
     methyladenine, 2-methylthio-adenine, 2-methoxy-adenine, inosine, i-methyl
     inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6
     thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7
     methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy
     guanosine, I -methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine,
     8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2
     methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.
 33. The isolated polynucleotide of claim 25, where the modifications are located on a
     nucleobase.
                                         949

WO 2013/151672                                                         PCT/US2013/030070
 34. The isolated polynucleotide of claim 33, where the modifications on the
     nucleobase are selected from the group consisting of cytosine, guanine, adenine,
     thymine and uracil.
 35. The isolated polynucleotide of claim 16, wherein the isolated polynucleotide is
     formulated.
 36. The isolated polynucleotide of claim 35, wherein the formulation comprises a
     lipid which is selected from one of DLin-DMA, DLin-K-DMA, DLin-KC2-DMA,
     98N12-5, C12-200, DLin-MC3-DMA, PLGA, PEG, PEG-DMG, PEGylated
     lipids and mixtures thereof.
 37. The isolated polynucleotide of claim 36, wherein the isolated polynucleotide is
     administered at a total daily dose of between 0.001 ug and 150 ug.
 38. The isolated polynucleotide of claim 37, wherein administration is by injection,
     topical administration, ophthalmic administration and intranasal administration.
 39. The isolated polynucleotide of claim 38, wherein administration is by injection
     and said injection is selected from the group consisting of intradermal,
     subcutaneous and intramuscular.
 40. The isolated polynucleotide of claim 39, wherein administration is topical
     administration and said topical administration is selected from the group
     consisting of cream, lotion, ointment, gel, spray, solution and the like.
 41. The isolated polynucleotide of claim 40, wherein the topical administration
     further comprises a penetration enhancer.
 42. The isolated polynucleotide of claim 41 where the penetration enhancer is
     selected from the group consisting of surfactants, fatty acids, bile salts, chelating
                                          950

WO 2013/151672                                                         PCT/US2013/030070
     agents, non-chelating non-surfactants, polyoxyethylene-9-lauryl ether,
     polyoxyethylene-20-cetyl ether, fatty acids and/or salts in combination with bile
     acids and/or salts, sodium salt in combination with lauric acid, capric acid and
     UDCA, and the like.
 43. The isolated polynucleotide of claim 16 further comprising a pharmaceutical
     acceptable excipient.
 44. The isolated polynucleotide of claim 43, wherein the pharmaceutical acceptable
     excipient is selected from the group consisting of a solvent, aqueous solvent, non
     aqueous solvent, dispersion media, diluent, dispersion, suspension aid, surface
     active agent, isotonic agent, thickening or emulsifying agent, preservative, lipid,
     lipidoids liposome, lipid nanoparticle, core-shell nanoparticles, polymer, lipoplex,
     peptide, protein, cell, hyaluronidase, and mixtures thereof.
 45. The isolated polynucleotide of claim 44, where the oncology-related composition
     further comprises a lipid and wherein said lipid is selected from DLin-DMA,
     DLin-K-DMA, DLin-KC2-DMA, 98N12-5, C12-200, DLin-MC3-DMA, PLGA,
     PEG, PEG-DMG, PEGylated lipids and mixtures thereof.
                                          951

<removed-apn> 19
           <removed-date>

<removed-apn> 19
           <removed-date>

<removed-apn> 19
           <removed-date>

<removed-apn> 19
           <removed-date>

<removed-apn> 19
           <removed-date>

                                       SEQUENCE LISTING
<removed-date>
19            DUE TO SIZE CONSIDERATIONS THE SEQUENCE LISTING FOR THIS DIVISIONAL
                   APPLICATION IS BEING FILED SEPARATELY BY PHYSICAL MEDIA
                                    DIRECT TO IP AUSTRALIA
<removed-apn>

